Daiichi Sankyo Company (4568N) Price & Analysis
4568N Stock Chart & Stats
- Day’s Range
- MXN 306.33 - MXN 306.33
- 52-Week Range
- MXN 281.00 - MXN 429.00
- Previous Close
- MXN 306.33
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 597.50B
- Enterprise Value
- MXN 4.94T
- Total Cash (Recent Filing)
- MXN 680.84B
- Total Debt (Recent Filing)
- MXN 500.33B
- Price to Earnings (P/E)
- 20.8
- Beta
- -0.15
- Next Earnings
- Jan 29, 2027
- EPS Estimate
- 5.28
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.17%
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Strong revenue growth demonstrates continued commercial traction in the company’s core medicines and supports operating scale. Reaching more than JPY 1 trillion by the second quarter, while retaining full-year guidance, provides a durable foundation for earnings growth over coming quarters.
Oncology Portfolio Momentum
The oncology portfolio is benefiting from deeper penetration, new indications, broader patient access and geographic launches. ENHERTU’s expanding use and DATROWAY’s accelerating adoption create multiple growth avenues, reducing reliance on a single indication and extending commercial momentum.
Balance Sheet Strength
Moderate leverage and robust returns on equity indicate a relatively strong financial base for an integrated pharmaceutical company. This balance-sheet capacity can support continued research, launches and strategic investment while providing some resilience if operating conditions soften.
Bears Say
Weak Cash Conversion
Poor conversion of reported earnings into cash can constrain financial flexibility even while profitability remains strong. Volatile free cash flow may make it harder to fund pipeline investment, absorb large payments and sustain capital allocation without relying on timing-dependent cash generation.
Margin Compression
Recent margin pressure suggests that higher costs or heavier investment are absorbing part of the benefit from revenue growth. If operating expenses continue to rise alongside development and commercialization activity, earnings growth may lag sales growth and profitability could remain below earlier peaks.
CMO Payment Exposure
The sizeable CMO-related payment creates a material near-term charge and adds uncertainty to reported profit and cash generation. Its expected concentration later in the fiscal year could amplify earnings volatility and reduce flexibility for research, launches or other corporate priorities.
Daiichi Sankyo Company News
Daiichi Sankyo Advances Dual Antibody-Drug Combo in Tough-to-Treat Breast Cancer
Daiichi Sankyo Company ($DSKYF) announced an update on their ongoing clinical study. The Phase 1b/2 HERTHENA-Breast02 trial, officially titled “A Phase 1b/2, Multicenter, Open-label, Dose Regimen Determination and Dose Expansion
Daiichi Sankyo’s R-DXd Trial Sets Up Next Catalyst in Ovarian Cancer Treatment
Daiichi Sankyo Company ($DSKYF) announced an update on their ongoing clinical study. The phase 3 REJOICE-Ovarian05 study tests Daiichi Sankyo’s raludotatug deruxtecan (R-DXd) in women with advanced ovarian and related
Daiichi Sankyo’s New Phase 3 Ovarian Cancer Trial Sets the Stage for Future Growth
Daiichi Sankyo Company ($DSKYF) announced an update on their ongoing clinical study. The Phase 3 REJOICE-Ovarian03 trial from Daiichi Sankyo targets women with platinum-sensitive recurrent ovarian and related cancers. Its
New Ovarian Cancer Maintenance Trial Puts Daiichi Sankyo’s R-DXd in the Late-Stage Spotlight
Daiichi Sankyo Company ($DSKYF) announced an update on their ongoing clinical study. The new Phase 3 study, officially titled “A Phase 3, Randomized, Open-label Study of Raludotatug Deruxtecan (MK-5909, R-DXd)
4568N FAQ
What was Daiichi Sankyo Company’s price range in the past 12 months?
What is Daiichi Sankyo Company’s market cap?
When is Daiichi Sankyo Company’s upcoming earnings report date?
How were Daiichi Sankyo Company’s earnings last quarter?
Is Daiichi Sankyo Company overvalued?
Does Daiichi Sankyo Company pay dividends?
What is Daiichi Sankyo Company’s EPS estimate?
How many shares outstanding does Daiichi Sankyo Company have?
What happened to Daiichi Sankyo Company’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Daiichi Sankyo Company?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Daiichi Sankyo Company
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Hiroyuki Okuzawa
- Employees
- 20,171
- Website
- www.daiichisankyo.com
- Address
- Daiichi Sankyo Building A/B, Tokyo, TY, 103-8426, JP
Daiichi Sankyo Company (4568N) Earnings & Revenues
4568N Company Deck
4568N Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. Revenue and core operating profit grew substantially, ENHERTU and DATROWAY showed strong commercial momentum, and the company reported multiple regulatory, clinical and strategic achievements. The main negative items were the withdrawn I-DXd accelerated approval filing, the delayed AVANZAR readout, regional revenue declines, higher expenses, CMO-related payments and the previously disclosed financial reporting corrections. These challenges were material but outweighed by the breadth and scale of the company's operating and pipeline progress.
View all MX:4568N earnings summaries4568N Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 0 | 5 |
| Technical Analysis | 2 | 0 | 1 |
| Moving Averages | 8 | 0 | 4 |